Newsroom | 4888 results

WENDELSHEIM, Germany--(BUSINESS WIRE)--MODAG GmbH announced it has received a $1 million research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This funding is part of MJFF’s strategic research agenda focused on supporting objective tools to biologically measure and track the progression of Parkinson’s disease (PD) to improve clinical trial design. The Foundation will support continued advancement of MODAG's innovative PET tracer programs, which enable earlier and mo...

GUILFORD, Conn.--(BUSINESS WIRE)--Swoop® portable MRI system receives CDSCO approval in India, expanding access to advanced brain imaging in a large, fast-growing healthcare market....

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) application to the U.S. Food and Drug Administration (FDA) seeking to expand the labeled indication for its RNS® System to include patients with antiseizure-medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic seizures....

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming J.P. Morgan 44th Annual Healthcare Conference. AtriCure’s management is scheduled to present on Wednesday, January 14, 2026, at 10:30 a.m. Pacific Standard Time. Interested parties may access a live aud...

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PT in San Francisco. About Autobahn Therapeutics Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychia...

NEW YORK--(BUSINESS WIRE)--Kallyope, a late-stage biotechnology company leveraging unique insights into neural signaling pathways to develop innovative therapies for health challenges faced by hundreds of millions of people globally, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference to be held January 12-15 in San Francisco, CA. 44th Annual J.P. Morgan Healthcare Conference Presentation Details Presentation Date: Tuesday, January 13, 2025 Present...

WENDELSHEIM, Deutschland--(BUSINESS WIRE)--Die MODAG GmbH gab heute bekannt, dass sie Fördermittel in Höhe von 1 Million US-Dollar von der Michael J. Fox Foundation for Parkinson’s Research (MJFF) erhalten hat. Diese Mittel sind Teil der strategischen Forschungsförderung der MJFF, die darauf abzielt, die Entwicklung objektiver Methoden zu unterstützen, die es ermöglichen bei Patienten mit Parkinson das Fortschreiten der Krankheit auf molekularer Ebene zu verfolgen. Dies soll auch das Design kli...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on December 15, 2025, it granted stock options to purchase an aggregate of 131,280 shares of common stock to el...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc. (“Encoded”), a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced the appointment of Dr. Joseph Sullivan M.D., as Vice President of Clinical Development. In this role, Dr. Sullivan will be responsible for leading all clinical development activities at Encoded and will report directly to the Company’s Chief Medical Officer, Sal Rico, M.D., Ph.D. “Joe’s unparal...

BERKELEY, Calif.--(BUSINESS WIRE)--Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis Complex-Related Epilepsy...